Literature DB >> 1445993

QSAR, diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium antagonists: a difficult road ahead.

P P Mager1, R A Coburn, A J Solo, D J Triggle, H Rothe.   

Abstract

Quantitative structure-activity relationships of a series of substituted 1,4-dihydropyridine calcium channel antagonists were studied. The analysis is difficult because of the problem of multicollinearity of substituent parameters, a high-leverage point, and position-dependent grouped observations. Canonical regression appears to be the method of choice. With respect to a maximum activity, it was shown that the following rank order of substituent parameters exists: Lipophilicity approximately ortho-position > inductivity > minimum width > meta-position. The molecular conformation of antagonists does not differ markedly (with exception of nifedipine derivatives and nimodipine), but differences seem to exist between the antagonists and the activator BAY K 8644.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445993

Source DB:  PubMed          Journal:  Drug Des Discov        ISSN: 1026-7921


  3 in total

1.  Synthesis and Vasorelaxant Effect of 9-aryl-1,8-acridinediones asPotassium Channel Openers in Isolated Rat Aorta.

Authors:  Mohsen Imenshahidi; Farzin Hadizadeh; Asieh Firoozeh-Moghadam; Mahmoud Seifi; Atefeh Shirinbak; Mohammad Bagher Gharedaghi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

2.  Antihypertensive effects of new dihydropyridine derivatives on phenylephrine-raised blood pressure in rats.

Authors:  Sara Rowghani Haghighi Fard; Ramin Miri; Ali Akbar Nekooeian
Journal:  Res Pharm Sci       Date:  2016-12

3.  Synthesis of Novel 4-[1-(4-fluorobenzyl)-5-imidazolyl] Dihydropyridines and Studying their Effects on Rat Blood Pressure.

Authors:  Seyed Ahmad Mohajeri; Hossein Hosseinzadeh; Sara Salami; Vahidehsadat Motamedshariaty; Mahmoud Seifi; Farzin Hadizadeh
Journal:  Iran J Basic Med Sci       Date:  2011-09       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.